Band 51
Progress in Drug Research
Aus der Reihe
Progress in Drug Research
-
- Hardcover
- Taschenbuch ausgewählt
-
Sprache:Englisch
-
Auflage:Softcover reprint of the original 1st ed. 1998
- Softcover reprint of the original 1st ed. 1999 Fr. 72.90
- Softcover reprint of the original 1st ed. 1998 Fr. 72.90 ausgewählt
- Softcover reprint of the original 1st ed. 1998 Fr. 137.00
- Softcover reprint of the original 1st ed. 1997 Fr. 72.90
- Softcover reprint of the original 1st ed. 1985 Fr. 72.90
- Softcover reprint of the original 1st edition 2003 Fr. 242.00
- Softcover reprint of the original 1st edition 2002 Fr. 242.00
- Softcover reprint of the original 1st ed. 1989 Fr. 72.90
- Softcover reprint of the original 1st ed. 2002 Fr. 242.00
- Softcover reprint of the original 1st ed. 2001 Fr. 138.00
- Softcover reprint of the original 1st ed. 2000 Fr. 72.90
- Softcover reprint of the original 1st ed. 2000 Fr. 72.90
- 1. Auflage Fr. 137.00
Fr. 72.90
inkl. gesetzl. MwSt.,
Beschreibung
Produktdetails
Einband
Taschenbuch
Erscheinungsdatum
12.11.2011
Abbildungen
VIII, 326 p.
Verlag
Springer BaselSeitenzahl
326
Maße (L/B/H)
24/17/1.9 cm
Gewicht
578 g
Auflage
Softcover reprint of the original 1st ed. 1998
Sprache
Englisch
ISBN
978-3-0348-9798-3
Due tothedevelopmentofdrugresistanceandotherlimitationsinthe treat ment of AIDS patients with reverse transcriptase (RT) inhibitors like zidovu dineandothers, itbecamenecessarytoexploreantiviralagentsactingontar getsotherthan RT. Inthepastfewyears, hundredsofHIVproteaseinhibitoLs have been synthesized and tested. Among these protease inhibitors, saquinavir, ritonavir, indinavir and nelfinavir have been marketed during 1995-1997. In this review, emphasis is placed on the development of HIV protease inhibitors as antiviral agents against HIV, structure-activity rela tionship (SAR) analysis ofsaquinavirand relatedcompounds, comparisonof four marketed HIV protease inhibitors, and future prospect in developing new anti-HIV drugs. 2 Introduction HIV protease inhibitors 3 HIV protease as a target for chemotherapy HIV protease was first suggested as a potential target for AIDS therapy by Kramer et a1. in 1986 [5]. HIV protease is a proteolytic enzyme responsible for cleaving large numbers of amino acid sequences. This enzyme regulates conversionoftheselargeaminoacid sequencesintobiologicallyactive struc tural and functional protein products. Specifically, HIV protease is responsi the enzymatic processing of the gagand gag-pol genes of HIV, which ble for encode for functional core proteins and viral enzymes (reverse transcriptase, ribonuclease H, integrase, and HIV protease). The polyproteins encoded by the gagand gag-pol genes undergo post-translational processing by HIV pro tease to form functional protein products as the viral particles budding out from infected cells. Therefore, inhibition of HIV protease by a protease inhibitor results in the release ofimmature, noninfectious viral particles [4].
Noch keine Bewertungen vorhanden
Verfassen Sie die erste Bewertung zu diesem Artikel
Helfen Sie anderen Kundinnen und Kunden durch Ihre Meinung.